No retraction, correction or concern found when last checked on Oct 16, 2026.

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Alexandra C. Walls, Brooke Fiala, Alexandra Schäfer and 39 more

Cell · 2020 · CC BY

doi:10.1016/j.cell.2020.10.043

Abstract

A safe, effective, and scalable vaccine is urgently needed to halt the ongoing SARS-CoV-2 pandemic. Here, we describe the structure-based design of self-assembling protein nanoparticle immunogens that elicit potent and protective antibody responses against SARS-CoV-2 in mice. The nanoparticle vaccines display 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly immunogenic array and induce neutralizing antibody titers roughly ten-fold higher than the prefusion-stabilized S ectodomain trimer despite a more than five-fold lower dose. Antibodies elicited by the nanoparticle immunogens target multiple distinct epitopes on the RBD, suggesting that they may not be easily susceptible to escape mutations, and exhibit a significantly lower binding:neutralizing ratio than convalescent human sera, which may minimize the risk of vaccine-associated enhanced respiratory disease. The high yield and stability of the protein components and assembled nanoparticles, especially compared to the SARS-CoV-2 prefusion-stabilized S trimer, suggest that manufacture of the nanoparticle vaccines will be highly scalable. These results highlight the utility of robust antigen display platforms for inducing potent neutralizing antibody responses and have launched cGMP manufacturing efforts to advance the lead RBD nanoparticle vaccine into the clinic.

Full text

Its licence does not allow us to show the full text. Read it at PubMed Central:

References 99

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.4049/jimmunol.2000583
2.
Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus · 2017
No notice
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1093/infdis/jiz070
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1126/science.aaf8818
5.
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies · 2020
No notice
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle · 2019
No notice
8.
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability · 2020
No notice
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1021/acsnano.8b02805
10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1038/s41586-020-2622-0
11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1073/pnas.1510199112
12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1016/j.cell.2020.06.035
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1128/jvi.00859-18
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1038/s41594-020-00547-5
16.
An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates · 2020
No notice
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1016/s0140-6736(20)31604-4
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1038/nmeth.1318
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1002/pro.3235
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1126/science.abb8923
21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1007/s13361-013-0727-5
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1038/s41594-020-0479-4
23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1016/j.cell.2020.02.052
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1016/j.cell.2020.05.042
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1038/nature18010
26.
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes · 2020
No notice
27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1016/j.chom.2020.07.002
28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1016/j.coi.2020.01.007
29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1056/nejmoa2022483
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1016/j.cell.2015.07.043
31.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1093/infdis/jiy745
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1101/cshperspect.a038448
33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1038/s41590-018-0305-x
34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1038/nature12202
35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1056/nejmoa2026920
36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1093/oxfordjournals.aje.a120955
37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1126/science.1219364
38.
Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis · 2018
Corrected
39.
Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies · 2018
No notice
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library10.1016/j.chroma.2013.10.087

All 99 references

Cited by papers we hold 23

Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment · 2024
No notice
De novo design of protein structure and function with RFdiffusion · 2023
No notice
Vaccine adjuvants: mechanisms and platforms · 2023
No notice
Current approaches of nanomedicines in the market and various stage of clinical translation · 2022
Not checked
mRNA-based therapeutics: powerful and versatile tools to combat diseases · 2022
No notice
Robust deep learning–based protein sequence design using ProteinMPNN · 2022
No notice
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection · 2022
No notice
COVID-19 vaccine development: milestones, lessons and prospects · 2022
No notice
Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases · 2022
No notice
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models · 2022
No notice
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines · 2022
No notice
A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections · 2021
Not checked
Pore-forming alpha-hemolysin efficiently improves the immunogenicity and protective efficacy of protein antigens. · 2021
Not checked
Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice · 2021
No notice
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection · 2021
No notice
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern · 2021
No notice
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses · 2021
No notice
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies · 2021
Corrected
Protein-based antigen presentation platforms for nanoparticle vaccines · 2021
No notice
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 · 2021
No notice

and 3 more

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.